32

Bioinformatics of the Brain

[72] J. J. Ferreira, R. Katzenschlager, B. R. Bloem, et al., “Summary of the

recommendations of the efns/mds‐es review on therapeutic management

of parkinson’s disease,” European Journal of Neurology, vol. 20, 2013.

[73] P. Maiti, J. Manna, and G. L. Dunbar, “Current understanding of the

molecular mechanisms in parkinson’s disease: Targets for potential treat-

ments,” Translational Neurodegeneration, vol. 6, 2017.

[74] R. Katzenschlager, C. Sampaio, J. Costa, et al., “Anticholinergics

for symptomatic management of parkinson’s disease,” The Cochrane

database of systematic reviews, vol. 2, p. CD003735, 2002.

[75] L. M. Fox, K. Kim, C. W. Johnson, et al., “Huntington’s disease patho-

genesis is modified in vivo by alfy/wdfy3 and selective macroautophagy,”

Neuron, vol. 105, pp. 813–821.e6, 2019.

[76] M. D. Thompson, W. M. Burnham, and D. E. C. Cole, “The g protein-

coupled receptors: Pharmacogenetics and disease,” Critical Reviews in

Clinical Laboratory Sciences, vol. 42, pp. 311–389, 2005.

[77] F. Zhang, L. Niu, X. Liu, et al., “Rapid eye movement sleep behavior dis-

order and neurodegenerative diseases: An update,” Aging and Disease,

vol. 11, pp. 315–326, 2020.

[78] A. Semaka, S. Creighton, S. C. Warby, et al., “Predictive testing for

huntington disease: interpretation and significance of intermediate alle-

les,” Clinical Genetics, vol. 70, 2006.

[79] M. D. Lezak, D. Howieson, D. W. Loring, et al., “Neuropsychological

assessment, 4th ed.,” 2004.

[80] M. P. Mattson and T. V. Arumugam, “Hallmarks of brain aging:

Adaptive and pathological modification by metabolic states,” Cell

metabolism, vol. 276, pp. 1176–1199, 2018.

[81] P. McColgan and S. J. Tabrizi, “Huntington’s disease: a clinical review,”

European Journal of Neurology, vol. 25, 2018.

[82] F. Saudou and S. Humbert, “The biology of huntingtin,” Neuron, vol. 89,

pp. 910–926, 2016.

[83] S. A. Johnson, J. C. Stout, A. C. Solomon, et al., “Beyond disgust:

impaired recognition of negative emotions prior to diagnosis in hunting-

ton’s disease,” Brain: a journal of neurology, vol. 130 Pt 7, pp. 1732–44,

2007.

[84] J. Y. Li, N. Popovic, and P. Brundin, “The use of the r6 transgenic

mouse models of huntington’s disease in attempts to develop novel ther-

apeutic strategies,” NeuroRX, vol. 2, pp. 447–464, 2005.